You are here Home Resources Handbook tables Handbook tables Table. Recommendations for MenACWY vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease Listen Print Share Twitter Facebook Email Age at start of vaccine course MenACWY vaccine brand Dose requirements for people with a specified medical condition associated with increased risk of meningococcal disease 6 weeks to 5 months Menveo Nimenrix 4 doses (8 weeks between doses; 4th dose at 12 months of age or 8 weeks after 3rd dose, whichever is later) 6–11 months Menveo Nimenrix 3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later) ≥12 months MenQuadfi Menveo Nimenrix 2 doses (8 weeks between doses) Booster doses for all agesa MenQuadfi Menveo Nimenrix For people with ongoing increased risk of invasive meningococcal disease who completed the primary series at: ≤6 years of age — 3 years after completing the primary schedule, then every 5 years after that ≥7 years of age — every 5 years after completing the primary schedule a People can receive booster doses using any brand of MenACWY vaccine. Related diseases Meningococcal disease Page history Last updated 7 December 2022 Last reviewed 7 December 2022 Is there anything wrong with this page? Help us improve the Australian Immunisation Handbook What you were doing? (required) What went wrong? (required) Leave this field blank
